Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Honest Company Inc (HNST) Price & Performance

BioNano Genomics IncTrade
Honest Company IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Honest Company Inc — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Honest Company Inc trades at $5.09 (market cap $558.95M). The key difference: Honest Company Inc is far larger — about 40.9× BioNano Genomics Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGOHNST
Market Cap
$13.66M$558.95M
Sector
HealthConsumer Staples
52-Week High
$4.92$5.46
52-Week Low
$1.06$2.10
Enterprise Value
$16.26M$462.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Honest Company Inc

HNST trades at $5.065, down 3.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue due to strategic exits. Despite negative net income margins and ROE, cash flow improved significantly in 2025 with $14.15M net cash flow. Analyst consensus shows 30% buy ratings amid ongoing profitability challenges.

The outlook remains cautious as strategic exits pressure revenue while cost improvements support margins. Investment opportunity exists if profitability targets are met, but risks include persistent net losses and competitive pressures in personal care markets. The stock's elevated P/E ratio of 48.83 requires careful valuation assessment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Honest Company Inc

The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.

Read more on HNST